ClinicalTrials.gg
CompletedNCT04074746Updated Sep 30, 2026Results posted

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

A Phase 1/2 interventional study of Anti-CD30/CD16A Monoclonal Antibody AFM13 and Cyclophosphamide in Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma and Recurrent Classic Hodgkin Lymphoma, sponsored by M.D. Anderson Cancer Center. Completed at 1 site in United States. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by M.D. Anderson Cancer Center · Phase 1/2, Interventional, and Treatment

How we know

Updated Sep 30, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
15 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Lymphoma, Large-Cell, Anaplastic by M.D. Anderson Cancer Center — none open to participants now, none under way, none of them phase 3. Lymphoma, Large-Cell, Anaplastic · M.D. Anderson Cancer Center.

Enrollment
Largest of 11
45 · median 2
Started
2020
the only one that year
Phase 1/2
4 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in Lymphoma, Large-Cell, Anaplastic by M.D. Anderson Cancer Center, this one has the largest enrollment, is the only one that started in 2020, is one of 4 in phase 1/2, and was the 11th registered.

Lymphoma, Large-Cell, Anaplastic

397 studies on the registry are indexed under Lymphoma, Large-Cell, Anaplastic; 26 are open to participants now.

Browse Lymphoma, Large-Cell, Anaplastic studies →

Open to participants now

None of the 11 studies in Lymphoma, Large-Cell, Anaplastic by M.D. Anderson Cancer Center is open now. The open studies under Lymphoma, Large-Cell, Anaplastic, anywhere →

Where they have run

Who these studies take

Of the 21 Lymphoma, Large-Cell, Anaplastic studies recruiting now, 12 (57%) set no upper age limit and 6 (29%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 15 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Lymphoma, Large-Cell, Anaplastic by M.D. Anderson Cancer Center as a file.
02

Study summary

This phase I/II trial studies the side effects and best dose of modified umbilical cord blood immune cells (natural killer [NK] cells) combined with the antibody AFM13 (AFM13-NK) and AFM13 alone in treating patients with CD30 positive Hodgkin lymphoma or non-Hodgkin lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as AFM13, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving AFM13 loaded with NK cells followed by AFM13 alone may kill more cancer cells and decrease cancer growth in patients with CD30 positive AFM13-NK Hodgkin and Non-Hodgkin lymphomas.

Read the detailed description

PRIMARY OBJECTIVE:

I. To establish the safety and recommended phase II dose of umbilical cord blood (CB)-derived natural killer (NK) cells preloaded with the bispecific antibody AFM13 (AFM13-NK), followed by intravenous anti-CD30/CD16A monoclonal antibody AFM13 (AFM13) in patients with refractory/relapsed CD30-positive lymphoid malignancies based on incidence of dose limiting toxicities (DLTs) per dose level. (Phase I) II. To assess the activity of umbilical cord blood (CB)-derived natural killer (NK) cells preloaded with the bispecific antibody AFM13 (AFM13- NK), followed by intravenous AFM13 in patients with refractory/relapsed CD30-positive lymphoid malignancies. based on overall response rate (ORR), complete response (CR) rate and partial response (PR) rate. (Phase II)

SECONDARY OBJECTIVES:

I. To evaluate the duration of response. II. To evaluate the event-free survival (EFS) rate. III. To evaluate the overall survival (OS) time. IV. To quantify the persistence of infused donor CB AFM13-NK cells in the recipient.

V. To conduct comprehensive immune reconstitution studies.

OUTLINE: This is a dose-escalation study of AFM13-NK.

Patients receive standard of care fludarabine intravenously (IV) over 1 hour and standard of care cyclophosphamide IV over 30-60 minutes on days -5 to -3, AFM13-NK IV over 4 hours on day 0, and then AFM13 IV over 4 hours on days 7, 14, and 21.

After completion of study treatment, patients are followed up at 28 days, 8 weeks, 100 and 180 days and then every 3-6 months for 2 years.

03

Conditions studied

  • Recurrent Anaplastic Large Cell Lymphoma
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • Recurrent Classic Hodgkin Lymphoma
  • Recurrent Mycosis Fungoides
  • Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Refractory Anaplastic Large Cell Lymphoma
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Refractory Mycosis Fungoides
  • Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
04

Who can participate

Ages eligible
15 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), mycosis fungoides (MF), or B-cell non-Hodgkin lymphoma with a pre-enrollment tumor positive for CD30 by immunohistochemistry at >= 1%. Patients with HL, ALCL and MF must be refractory or intolerant to brentuximab vedotin.
  • performance status >= 60%.
  • >= 500/mm\^3
  • count >= 50,000/mm\^3
  • Serum >= 50 ml/min, estimated using the Cockcroft-Gault equation.
  • (ALT) and/or aspartate aminotransferase (AST) =\< 3 x (ULN).
  • =\< 2 x ULN.
  • Alkaline phosphatase (ALP) =\< 2 x ULN.
  • (FEV1) >= 50%
  • Forced vital capacity (FVC) >= 50%
  • Carbon monoxide diffusing capability test (DLCO) (corrected for [Hgb]) >= 50%
  • >= 40%.
  • No uncontrolled arrhythmias or symptomatic cardiac disease.
  • If female of , must not be pregnant or be breastfeeding and required to have a negative urine or serum pregnancy test within 3 days prior to the first dose of study drug.

    • Note: Urine pregnancy tests that cannot be confirmed as negative, require a confirmatory negative serum pregnancy test. In addition, females of childbearing potential must agree use of a highly effective method of for the course of the study from 14 days prior to the first dose of study drug until 60 days after the last dose of study drug. Non-childbearing potential is defined as: : defined as no menses for 12 months without an alternative medical cause. A high follicle-stimulating hormone (FSH) level in the postmenopausal range may be used to confirm post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, FSH measurements indicating post-menopausal status must be documented in patient's medical history. Permanently sterile: documented permanent sterilization e.g. hysterectomy, bilateral salpingectomy and bilateral oophorectomy. If male, surgically sterile or agrees to use a highly effective method of contraception, 14 days prior to the first dose of study drug until 60 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Major surgery \< 4 weeks prior to first dose of study drug.
  • Any other severe or uncontrolled disease or condition which might increase the risk associated with study participation.
  • Any other known to be active, with the exception of treated cervical intra-epithelial neoplasia and non-melanoma skin cancer.
  • Grade >= 3 non-hematologic toxicity from prior therapy that has not resolved to grade =\< 2.
  • Active , either active carrier (hepatitis B surface antigen positive [HBsAg +]) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >= 10,000 copies/mL, or >= 2,000 IU/mL), or (detectable viral load by hepatitis C virus [HCV] ribonucleic acid [RNA] polymerase chain reaction [PCR]).
  • Active infection requiring parenteral antibiotics.
  • (HIV) infection.
  • Treatment within prior 2 weeks with any anti-cancer agent, or approved.
  • Active central nervous system (CNS) involvement (untreated parenchymal or positive cytology of cerebrospinal fluid).
  • =\< 6 months.
  • Previous treatment with AFM13.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Treatment (AFM13-NK, AFM13)

    Patients receive standard of care fludarabine IV over 1 hour and standard of care cyclophosphamide IV over 30-60 minutes on days -5 to -3, AFM13-NK IV over 4 hours on day 0, and then AFM13 IV over 4 hours on days 7, 14, and 21.

    Biological: Anti-CD30/CD16A Monoclonal Antibody AFM13 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Fludarabine Phosphate · Biological: Genetically Engineered Lymphocyte Therapy

Interventions

  • BiologicalAnti-CD30/CD16A Monoclonal Antibody AFM13

    Drug page: AFM13Studies of AFM13AFM13 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: AFM13

  • Given IV

    Also known as: (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719

  • Given IV

    Also known as: Fluradosa

  • Given IV

    Also known as: 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586

  • BiologicalGenetically Engineered Lymphocyte Therapy

    Given AFM13-NK cells IV

06

What researchers measure

Primary outcomes

  1. Maximum Tolerate Dose of AFM13 Umbilical Cord Blood(UCB) Derived Natural Killer(NK) Cells Infused on D=0,D+7,D+14,D+21 for Each Cohort (1x10^6,1x10^7,1x10^8).

    Number of Participants who have experienced Dose-limiting toxicity (DLT) during AFM13-NK cell infusions. DLT will be defined as any related grade 3 or greater non- hematologic toxicity that occurs within 28 days of AFM13-NK infusion

    Time frame: 28 days post AFM13-NK cells on D=0 for each Cohort.

Secondary outcomes

  1. Number of Participants That Achieved Complete Response (CR) Post AFM13-NK Cell Infusions.

    Complete Remission requires all of the following: Complete metabolic response by PET-CT: Score 1-3. Score 1 (no uptake above the background), Score 2 (uptake is less than or equal to the mediastinal blood pool), or Score 3 (uptake is greater than the mediastinal blood pool but less than or equal to the normal liver) with or without a residual mass on 5 point scale or on CT, target nodes/nodal masses must regress to ≤ 1.5 cm in Di. Lyric Response Criteria (Appendix 2): Complete Response (CR): PET-CT Scores 1-3 Partial Response (PR): PET-CT Scores 4-5 with reduced uptake compared with baseline. Progression Disease (PD): PET-CT Scores 4-5 with an increased uptake compared to baseline or new and/or regrowth of measurable lesions.

    Time frame: Time Frame: 1 year post AFM13-NK cells on D=0

07

Results

Posted Sep 30, 2026

Participant flow

Participant flow — Overall Study
MilestonePhase I_ Cohort 1(1x10^6/kg)Phase I_ Cohort 2(1x10^7/kgPhase I_ Cohort 3(1x10^8/kg)Phase II_ Cohort 3(1x10^8/kg)
Started33435
Completed33333
Not completed0012
Withdrew: Infection0011
Withdrew: Physician decision0001

Outcome measures

PrimaryMaximum Tolerate Dose of AFM13 Umbilical Cord Blood(UCB) Derived Natural Killer(NK) Cells Infused on D=0,D+7,D+14,D+21 for Each Cohort (1x10^6,1x10^7,1x10^8).

Number of Participants who have experienced Dose-limiting toxicity (DLT) during AFM13-NK cell infusions. DLT will be defined as any related grade 3 or greater non- hematologic toxicity that occurs within 28 days of AFM13-NK infusion

Time frame:
28 days post AFM13-NK cells on D=0 for each Cohort.
Reported as:
Count of participants · Participants
Maximum Tolerate Dose of AFM13 Umbilical Cord Blood(UCB) Derived Natural Killer(NK) Cells Infused on D=0,D+7,D+14,D+21 for Each Cohort (1x10^6,1x10^7,1x10^8).
ParticipantsPhase I_ Cohort 1(1x10^6/kg)Phase I_ Cohort 2(1x10^7/kg)Phase I_ Cohort 3(1x10^8/kg)Phase II_ Cohort 3(1x10^8/kg)
Maximum Tolerate Dose of AFM13 Umbilical Cord Blood(UCB) Derived Natural Killer(NK) Cells Infused on D=0,D+7,D+14,D+21 for Each Cohort (1x10^6,1x10^7,1x10^8).0000
SecondaryNumber of Participants That Achieved Complete Response (CR) Post AFM13-NK Cell Infusions.

Complete Remission requires all of the following: Complete metabolic response by PET-CT: Score 1-3. Score 1 (no uptake above the background), Score 2 (uptake is less than or equal to the mediastinal blood pool), or Score 3 (uptake is greater than the mediastinal blood pool but less than or equal to the normal liver) with or without a residual mass on 5 point scale or on CT, target nodes/nodal masses must regress to ≤ 1.5 cm in Di. Lyric Response Criteria (Appendix 2): Complete Response (CR): PET-CT Scores 1-3 Partial Response (PR): PET-CT Scores 4-5 with reduced uptake compared with baseline. Progression Disease (PD): PET-CT Scores 4-5 with an increased uptake compared to baseline or new and/or regrowth of measurable lesions.

Time frame:
Time Frame: 1 year post AFM13-NK cells on D=0
Reported as:
Count of participants · Participants
Number of Participants That Achieved Complete Response (CR) Post AFM13-NK Cell Infusions.
ParticipantsPhase I_ Cohort 1(1x10^6/kg)Phase I_ Cohort 2(1x10^7/kg)Phase I_ Cohort 3(1x10^8/kg)Phase II_ Cohort 3(1x10^8/kg)
Number of Participants That Achieved Complete Response (CR) Post AFM13-NK Cell Infusions.11323

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I_ Cohort 1(1x10^6/kg)2/3 (66.7%)0/3 (0%)2/3 (66.7%)
Phase I_ Cohort 2(1x10^7/kg)2/3 (66.7%)0/3 (0%)3/3 (100%)
Phase I_ Cohort 3(1x10^8/kg)2/4 (50%)0/4 (0%)1/4 (25%)
Phase II_ Cohort 3(1x10^8/kg)14/35 (40%)0/35 (0%)9/35 (25.7%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPhase I_ Cohort 1(1x10^6/kg)Phase I_ Cohort 2(1x10^7/kg)Phase I_ Cohort 3(1x10^8/kg)Phase II_ Cohort 3(1x10^8/kg)
ChillsGeneral disorders1/33/31/45/35
FeverGeneral disorders1/32/31/42/35
PruritusSkin and subcutaneous tissue disorders2/30/30/40/35
Alanine aminotransferase increasedInvestigations1/30/30/40/35
Aspartate aminotransferase increasedInvestigations1/30/30/40/35
HeadacheNervous system disorders1/30/30/40/35
HypotensionVascular disorders1/30/30/43/35
Infusion related reactionInjury, poisoning and procedural complications1/30/30/49/35
Flank painMusculoskeletal and connective tissue disorders0/31/30/40/35
Sinus tachycardiaCardiac disorders0/31/30/40/35

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase I_ Cohort 1(1x10^6/kg)Phase I_ Cohort 2(1x10^7/kg)Phase I_ Cohort 3(1x10^8/kg)Phase II_ Cohort 3(1x10^8/kg)Total
<=18 years00000
Between 18 and 65 years3233139
>=65 years01146
Sex: Female, Male
Sex: Female, Male(Participants)Phase I_ Cohort 1(1x10^6/kg)Phase I_ Cohort 2(1x10^7/kg)Phase I_ Cohort 3(1x10^8/kg)Phase II_ Cohort 3(1x10^8/kg)Total
Female1021215
Male2322330
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase I_ Cohort 1(1x10^6/kg)Phase I_ Cohort 2(1x10^7/kg)Phase I_ Cohort 3(1x10^8/kg)Phase II_ Cohort 3(1x10^8/kg)Total
Hispanic or Latino11125
Not Hispanic or Latino2233340
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Phase I_ Cohort 1(1x10^6/kg)Phase I_ Cohort 2(1x10^7/kg)Phase I_ Cohort 3(1x10^8/kg)Phase II_ Cohort 3(1x10^8/kg)Total
United States3343545
08

Study locations

1 site
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, Rafei H, Kerbauy LN, Kaplan M, Marin D, Griffin L, Barnett M, Bassett R, Uprety N, Shrestha R, Silva FR, Islam S, Ganesh C, Borneo Z, Ramdial J, Ramirez A, Hosing C, Alousi A, Popat U, Qazilbash M, Ahmed S, Iyer S, Sainz TP, Vega F, Fowlkes NW, Alexis K, Emig M, Harstrick A, Overesch A, Shpall EJ, Rezvani K. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med. 2025 Jun;31(6):1987-1993. doi: 10.1038/s41591-025-03640-8. Epub 2025 Apr 4. PubMed 40186077 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Sep 2025, 62 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 15 phase 1/2 interventional studies under Lymphoma, Large-Cell, Anaplastic, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 92. This study's 62 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2019
First posted
Aug 30, 2019
StartActual
Jul 18, 2020
Primary completionActual
Sep 23, 2025
CompletionActual
Sep 23, 2025
Results first posted
Sep 30, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 30, 2026
Primary completion
Sep 22, 2025→Sep 23, 2025
Sep 30, 2026
Study completion
Sep 22, 2025→Sep 23, 2025
Sep 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Incidence of adverse eventsNow Maximum Tolerate Dose of AFM13 Umbilical Cord Blood(UCB) Derived Natural Killer(NK) Cells Infused on D=0,D+7,D+14,D+21 for Each Cohort (1x10^6,1x10^7,1x10^8).Time frame: Up to 2 years → 28 days post AFM13-NK cells on D=0 for each Cohort.
Sep 30, 2026
Documents
Secondary outcomes
1 added, 8 removed
What changed in the outcomes
  • AddedNumber of Participants That Achieved Complete Response (CR) Post AFM13-NK Cell Infusions.Time frame: Time Frame: 1 year post AFM13-NK cells on D=0
  • RemovedOverall survivalTime frame: Up to 2 years
  • RemovedEvent-free survivalTime frame: Up to 2 years
  • RemovedOverall response rate (ORR)Time frame: Up to 2 years
  • RemovedComplete response (CR) rateTime frame: Up to 2 years
  • RemovedPartial response (PR) rateTime frame: Up to 2 years
  • RemovedDuration of responseTime frame: Time of initial response to disease relapse/progression, assessed up to 2 years
  • RemovedPersistence of infused donor AFM13-NK cellsTime frame: Up to 2 years
  • RemovedImmune reconstitution studiesTime frame: Up to 2 years
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Results posted
    Primary completion Sep 22, 2025→Sep 23, 2025
    Study completion Sep 22, 2025→Sep 23, 2025
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Incidence of adverse eventsNow Maximum Tolerate Dose of AFM13 Umbilical Cord Blood(UCB) Derived Natural Killer(NK) Cells Infused on D=0,D+7,D+14,D+21 for Each Cohort (1x10^6,1x10^7,1x10^8).Time frame: Up to 2 years → 28 days post AFM13-NK cells on D=0 for each Cohort.
    Secondary outcomes 1 added, 8 removed
    What changed in the outcomes
    • AddedNumber of Participants That Achieved Complete Response (CR) Post AFM13-NK Cell Infusions.Time frame: Time Frame: 1 year post AFM13-NK cells on D=0
    • RemovedOverall survivalTime frame: Up to 2 years
    • RemovedEvent-free survivalTime frame: Up to 2 years
    • RemovedOverall response rate (ORR)Time frame: Up to 2 years
    • RemovedComplete response (CR) rateTime frame: Up to 2 years
    • RemovedPartial response (PR) rateTime frame: Up to 2 years
    • RemovedDuration of responseTime frame: Time of initial response to disease relapse/progression, assessed up to 2 years
    • RemovedPersistence of infused donor AFM13-NK cellsTime frame: Up to 2 years
    • RemovedImmune reconstitution studiesTime frame: Up to 2 years
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04074746
Responsible party
Sponsor
First posted
Aug 30, 2019
Start date
Jul 18, 2020
Primary completion
Sep 23, 2025
Completion
Sep 23, 2025
Results posted
Sep 30, 2026
Last update
Sep 30, 2026

Study contacts

Yago L Nieto
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AFM13

Start the discussion